Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality
Abstract
Objective Whether peginterferon α and ribavirin combination therapy reduces risk of hepatocellular carcinoma (HCC) or improves survival in patients dual-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) is unknown. Since it is ethically impossible to conduct a randomised trial to learn the long-term efficacy, we rely upon the large database to explore the effectiveness of combination therapy among dual-infected patients. Design Data for this population-based retrospective cohort study were obtained from the treatment programme, Cancer Registry, National Health Insurance and death certification. We examined the risk of HCC, mortality and adverse events in 1096 treated and 18 988 untreated HCV–HBV dually-infected patients. Outcomes were analysed using the bias corrected inverse probability weighting (IPW) by propensity scores. Outcomes of HCV–HBV dually-infected and HCV mono-infected patients receiving the same treatment were compared using new user design with IPW estimators to adjust for confounding. Results After adjustment, combination therapy significantly reduced the risk of HCC (HR 0.76, 95% CI 0.59 to 0.97), liver-related mortality (HR 0.47, 95% CI 0.37 to 0.6) and all-cause mortality (HR 0.42, 95% CI 0.34 to 0.52). Nevertheless, the underlying HBV infection was still a risk factor for HCC and mortality after treatment. Treatment was associated with an increase in the incidence of thyroid dysfunction (HR 1.9, pConclusions This is the first evidence showing that combination therapy decreased the risk of HCC and improved survival in HCV–HBV dually-infected patients despite a slight increase in the incidence of thyroid and mood disorders.Keywords
This publication has 30 references indexed in Scilit:
- Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C VirusesPLOS ONE, 2011
- Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesisEuropean Journal of Cancer, 2010
- A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C VirusClinical Gastroenterology and Hepatology, 2010
- Dual chronic hepatitis B virus and hepatitis C virus infectionHepatology International, 2009
- The Secret of Immortal Time Bias in Epidemiologic StudiesJournal of the American Society of Nephrology, 2008
- Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infectionJournal of Gastroenterology and Hepatology, 2005
- Ribavirin and Interferon Is Effective for Hepatitis C Virus Clearance in Hepatitis B and C Dually Infected PatientsHepatology, 2003
- Role of hepatitis C virus in dual and triple hepatitis virus infection*1Hepatology, 1995
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: A responseJournal of Clinical Epidemiology, 1993
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993